Open Payments

National Jewish Health

Type
Teaching hospital
Where
Denver, CO
Medicare CCN
060107
Received
$6,208,844 in 321 records, 2023 ($2,665,886 general, $3,542,958 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment95$2,665,886
2023Research payment226$3,542,958

By company

CompanyRecordsAmountYears
GENZYME CORPORATION6$1,052,8772023
AstraZeneca Pharmaceuticals LP13$845,5532023
SANOFI US SERVICES INC.17$789,4822023
Insmed, Inc.51$513,4002023
Boehringer Ingelheim Pharmaceuticals, Inc.7$463,9282023
Novartis Pharmaceuticals Corporation4$455,6112023
PFIZER INC.2$376,0132023
Apellis Pharmaceuticals, Inc.32$323,9062023
Alexion Pharmaceuticals, Inc.28$266,7022023
Paratek Pharmaceuticals, Inc.13$230,7712023
VERTEX PHARMACEUTICALS INCORPORATED5$230,6642023
United Therapeutics Corporation21$121,9262023
Janssen Research & Development, LLC10$85,7022023
Roche Products Limited14$53,2892023
Janssen Scientific Affairs, LLC1$50,0002023
E.R. Squibb & Sons, L.L.C.1$47,8842023
Regeneron Healthcare Solutions, Inc.1$47,5002023
Regeneron Pharmaceuticals, Inc.33$37,2332023
Genentech, Inc.12$27,7102023
Rhythm Pharmaceuticals, Inc.1$25,0002023
Life Technologies Corporation1$20,6602023
Mylan Specialty L.P.1$20,0002023
Bayer Healthcare Pharmaceuticals Inc.1$20,0002023
Merck Sharp & Dohme LLC3$19,6412023
Allerderm Laboratories1$17,4162023
Beckman Coulter, Inc.1$10,0002023
Boehringer Ingelheim International GmbH2$7,7372023
GlaxoSmithKline, LLC.2$6,5002023
Electromed, Inc.2$6,0002023
Grifols USA, LLC2$5,0002023
ABBVIE INC.1$3,5002023
Genentech USA, Inc.1$3,5002023
Optinose US, Inc.1$3,5002023
Aimmune Therapeutics, Inc.1$3,2002023
CSL Behring1$3,0002023
Ipsen Bioscience Inc.1$2,9902023
EMD Millipore Corporation1$2,5002023
Amgen Inc.2$2,5002023
Becton, Dickinson and Company18$2,1312023
AstraZeneca UK Limited1$2,0402023
Alkermes, Inc.1$1,0002023
Siemens Medical Solutions USA, Inc.1$5102023
Fisher Scientific Company L.L.C.1$2102023
Bio-Rad Laboratories, Inc.1$1022023
Luminex Corporation1$442023

By nature of payment

NatureRecordsAmount
Research payment226$3,542,958
Grant16$2,263,525
Compensation for services other than consulting, including serving as faculty or as a speaker at a v30$277,702
Space rental or facility fees (teaching hospital only)14$48,500
Royalty or License26$45,894
Gift1$15,000
Education3$8,500
Food and Beverage2$6,000
Debt forgiveness1$510
Consulting Fee1$210
Honoraria1$44

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-31Merck Sharp & Dohme LLC$11,084Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot2023
2023-12-31Siemens Medical Solutions USA, Inc.$510Debt forgivenessIn-kind items and services2023
2023-12-27United Therapeutics Corporation$11,254Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-12-27United Therapeutics Corporation$3,500EducationCash or cash equivalent2023
2023-12-25AstraZeneca Pharmaceuticals LP$7,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentTEZSPIRE Biological, Respiratory2023
2023-12-21Apellis Pharmaceuticals, Inc.$12,685Research paymentCash or cash equivalent2023
2023-12-21Apellis Pharmaceuticals, Inc.$500Research paymentCash or cash equivalent2023
2023-12-20Insmed, Inc.$1,633Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-12-20Insmed, Inc.$1,217Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-12-20Insmed, Inc.$1,098Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-12-20Insmed, Inc.$1,098Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-12-20Insmed, Inc.$629Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-12-20Insmed, Inc.$59Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-12-20Insmed, Inc.$59Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-12-19Electromed, Inc.$3,500Food and BeverageCash or cash equivalentSMARTVEST Device, HFCWO2023
2023-12-19Regeneron Pharmaceuticals, Inc.$280Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-12-18Janssen Research & Development, LLC$11,737Research paymentCash or cash equivalentA Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co2023
2023-12-18Apellis Pharmaceuticals, Inc.$6,752Research paymentCash or cash equivalent2023
2023-12-18Apellis Pharmaceuticals, Inc.$5,748Research paymentCash or cash equivalent2023
2023-12-18Janssen Research & Development, LLC$3,692Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2023
2023-12-18Fisher Scientific Company L.L.C.$210Consulting FeeCash or cash equivalent2023
2023-12-14Alexion Pharmaceuticals, Inc.$23,750Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-12-14Alexion Pharmaceuticals, Inc.$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-12-12United Therapeutics Corporation$5,692Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-12-12United Therapeutics Corporation$3,500Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-12-12Regeneron Pharmaceuticals, Inc.$280Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-12-08Life Technologies Corporation$20,660Royalty or License (17 payments)Cash or cash equivalentMonoclonal Antibodies Device, Mouse Hybridoma Cell Line2023
2023-12-08Regeneron Pharmaceuticals, Inc.$224Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-12-06GlaxoSmithKline, LLC.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentNUCALA Biological, IMMUNOLOGY2023
2023-12-04AstraZeneca Pharmaceuticals LP$130,500GrantCash or cash equivalent2023
2023-12-01SANOFI US SERVICES INC.$61,947Research paymentCash or cash equivalentREGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis2023
2023-12-01Amgen Inc.$1,250Royalty or LicenseCash or cash equivalent2023
2023-12-01Amgen Inc.$1,250Royalty or LicenseCash or cash equivalent2023
2023-11-29Apellis Pharmaceuticals, Inc.$20,000Research paymentCash or cash equivalentPhase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex 2023
2023-11-29Apellis Pharmaceuticals, Inc.$1,575Research paymentCash or cash equivalentA Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)2023
2023-11-29Apellis Pharmaceuticals, Inc.$784Research paymentCash or cash equivalentPhase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies2023
2023-11-28AstraZeneca Pharmaceuticals LP$126,483GrantCash or cash equivalent2023
2023-11-28Regeneron Pharmaceuticals, Inc.$336Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-11-23Alexion Pharmaceuticals, Inc.$14,040Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-11-23Alexion Pharmaceuticals, Inc.$5,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-11-23Alexion Pharmaceuticals, Inc.$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-11-22Regeneron Healthcare Solutions, Inc.$47,500GrantCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY2023
2023-11-21Regeneron Pharmaceuticals, Inc.$224Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-11-20Boehringer Ingelheim Pharmaceuticals, Inc.$33,040Research paymentCash or cash equivalentOFEV Drug, RESPIRATORYCT scans using deep learning to assess lung fibros2023
2023-11-20AstraZeneca Pharmaceuticals LP$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentFASENRA Biological, Respiratory2023
2023-11-17Regeneron Pharmaceuticals, Inc.$1,232Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-11-17Becton, Dickinson and Company$534Royalty or LicenseCash or cash equivalentHorizon Device, Reagents2023
2023-11-17Becton, Dickinson and Company$153Royalty or LicenseCash or cash equivalent2023
2023-11-17Becton, Dickinson and Company$148Royalty or LicenseCash or cash equivalent2023
2023-11-17Becton, Dickinson and Company$38Royalty or LicenseCash or cash equivalent2023
2023-11-14Boehringer Ingelheim Pharmaceuticals, Inc.$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2023
2023-11-13CSL Behring$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2023
2023-11-10Apellis Pharmaceuticals, Inc.$500Research paymentCash or cash equivalent2023
2023-11-07Paratek Pharmaceuticals, Inc.$24,309Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTICA Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe2023
2023-11-07Paratek Pharmaceuticals, Inc.$19,856Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTICMIC Testing on Retrospectively Collected Isolates2023
2023-11-07United Therapeutics Corporation$4,758Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-11-01SANOFI US SERVICES INC.$61,947Research paymentCash or cash equivalentREGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis2023
2023-10-31Paratek Pharmaceuticals, Inc.$16,738Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTICA Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe2023
2023-10-31Beckman Coulter, Inc.$10,000Royalty or LicenseCash or cash equivalent2023
2023-10-27Insmed, Inc.$2,926Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-10-27Insmed, Inc.$1,862Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcom2023
2023-10-26Apellis Pharmaceuticals, Inc.$24,850Research paymentCash or cash equivalentPhase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies2023
2023-10-26Apellis Pharmaceuticals, Inc.$8,500Research paymentCash or cash equivalentPhase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex 2023
2023-10-26Novartis Pharmaceuticals Corporation$6,131Research paymentCash or cash equivalentA 52 week multicenter randomized double blind placebocontrolled study to assess the efficacy and safety of QAW039 when a2023
2023-10-26Apellis Pharmaceuticals, Inc.$2,250Research paymentCash or cash equivalentStudy Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN2023
2023-10-26Apellis Pharmaceuticals, Inc.$900Research paymentCash or cash equivalentA Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)2023
2023-10-26Apellis Pharmaceuticals, Inc.$185Research paymentCash or cash equivalent2023
2023-10-25Regeneron Pharmaceuticals, Inc.$3,221Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-10-25Regeneron Pharmaceuticals, Inc.$336Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-10-22AstraZeneca Pharmaceuticals LP$15,000GiftCash or cash equivalentTEZSPIRE Biological, Respiratory2023
2023-10-20SANOFI US SERVICES INC.$2,800Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patient2023
2023-10-19Alexion Pharmaceuticals, Inc.$30,125Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-10-19Janssen Research & Development, LLC$4,533Research paymentCash or cash equivalentA Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co2023
2023-10-19Alexion Pharmaceuticals, Inc.$1,740Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-10-17United Therapeutics Corporation$14,057Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-10-17United Therapeutics Corporation$10,201Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-10-17Genentech, Inc.$4,000Research paymentCash or cash equivalentTecentriq Biological, BioOncology1LM SCLC Tecentriq Lurbinectedin2023
2023-10-17AstraZeneca Pharmaceuticals LP$3,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-10-12Genentech, Inc.$294Research paymentCash or cash equivalentXolair Biological, ImmunologyMeasuring Responses to Xolair Omalizumab using mHealth Technologies2023
2023-10-10GENZYME CORPORATION$961,330Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie2023
2023-10-10Regeneron Pharmaceuticals, Inc.$112Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-10-06Apellis Pharmaceuticals, Inc.$8,250Research paymentCash or cash equivalentPhase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex 2023
2023-10-03Regeneron Pharmaceuticals, Inc.$448Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-10-03Regeneron Pharmaceuticals, Inc.$336Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-10-02AstraZeneca Pharmaceuticals LP$7,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-10-02Insmed, Inc.$1,656Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-02Insmed, Inc.$1,610Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-02Insmed, Inc.$1,574Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-02Insmed, Inc.$629Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-02Insmed, Inc.$629Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-02Insmed, Inc.$83Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-02Insmed, Inc.$83Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-02Insmed, Inc.$30Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-02Insmed, Inc.$29Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-10-01SANOFI US SERVICES INC.$61,947Research paymentCash or cash equivalentREGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis2023
2023-09-28Apellis Pharmaceuticals, Inc.$13,209Research paymentCash or cash equivalentPhase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies2023
2023-09-28Apellis Pharmaceuticals, Inc.$9,500Research paymentCash or cash equivalentPhase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex 2023
2023-09-28Apellis Pharmaceuticals, Inc.$7,100Research paymentCash or cash equivalent2023
2023-09-28Alexion Pharmaceuticals, Inc.$4,375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-09-28Apellis Pharmaceuticals, Inc.$900Research paymentCash or cash equivalentA Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)2023
2023-09-28Apellis Pharmaceuticals, Inc.$500Research paymentCash or cash equivalent2023
2023-09-28Apellis Pharmaceuticals, Inc.$250Research paymentCash or cash equivalentStudy Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN2023
2023-09-21Alexion Pharmaceuticals, Inc.$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-09-19Boehringer Ingelheim Pharmaceuticals, Inc.$74,948Research paymentCash or cash equivalentPDE4 Phase III trial in PF ILD2023
2023-09-18Genentech, Inc.$2,103Research paymentCash or cash equivalentXolair Biological, ImmunologyMeasuring Responses to Xolair Omalizumab using mHealth Technologies2023
2023-09-18Genentech, Inc.$1,357Research paymentCash or cash equivalentXolair Biological, ImmunologyMeasuring Responses to Xolair Omalizumab using mHealth Technologies2023
2023-09-14Alexion Pharmaceuticals, Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-09-12Genentech USA, Inc.$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentXolair Biological, Immunology2023
2023-09-12Regeneron Pharmaceuticals, Inc.$336Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-09-07SANOFI US SERVICES INC.$3,000Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyA Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patient2023
2023-09-06United Therapeutics Corporation$7,028Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-09-06United Therapeutics Corporation$1,025Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-09-06Regeneron Pharmaceuticals, Inc.$224Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-09-05Bayer Healthcare Pharmaceuticals Inc.$20,000Research paymentCash or cash equivalentPHAB 3.0 Award Agreement2023
2023-09-01SANOFI US SERVICES INC.$61,947Research paymentCash or cash equivalentREGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis2023
2023-09-01Allerderm Laboratories$17,416Research paymentCash or cash equivalentMetal Allergen Safety and Efficacy2023
2023-09-01Alexion Pharmaceuticals, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-09-01Regeneron Pharmaceuticals, Inc.$336Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-08-30Apellis Pharmaceuticals, Inc.$11,190Research paymentCash or cash equivalent2023
2023-08-30Apellis Pharmaceuticals, Inc.$6,773Research paymentCash or cash equivalentStudy Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN2023
2023-08-30Apellis Pharmaceuticals, Inc.$500Research paymentCash or cash equivalent2023
2023-08-29Paratek Pharmaceuticals, Inc.$32,983Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTICA Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe2023
2023-08-25Janssen Research & Development, LLC$1,739Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2023
2023-08-24Alexion Pharmaceuticals, Inc.$3,125Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-08-24Alexion Pharmaceuticals, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-08-24Becton, Dickinson and Company$333Royalty or LicenseCash or cash equivalentHorizon Device, Reagents2023
2023-08-24Becton, Dickinson and Company$250Royalty or LicenseCash or cash equivalent2023
2023-08-24Becton, Dickinson and Company$31Royalty or LicenseCash or cash equivalent2023
2023-08-24Becton, Dickinson and Company$13Royalty or LicenseCash or cash equivalent2023
2023-08-24Becton, Dickinson and Company$8Royalty or LicenseCash or cash equivalent2023
2023-08-23Regeneron Pharmaceuticals, Inc.$5,518Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-08-18AstraZeneca Pharmaceuticals LP$199,267GrantCash or cash equivalent2023
2023-08-15Roche Products Limited$1,880Research paymentCash or cash equivalentEsbriet Biological, ImmunologyPh III OLE Trial to Evaluate Long term Safety and Efficacy of PRM 151 in Patients with IPF2023
2023-08-14Roche Products Limited$1,005Research paymentCash or cash equivalentEsbriet Biological, ImmunologyTrial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis2023
2023-08-14Roche Products Limited$1,005Research paymentCash or cash equivalentEsbriet Biological, ImmunologyTrial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis2023
2023-08-08Paratek Pharmaceuticals, Inc.$10,328Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTICA Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe2023
2023-08-08EMD Millipore Corporation$2,500Royalty or LicenseCash or cash equivalent Device, DIAGNOSTIC TESTING2023
2023-08-04Apellis Pharmaceuticals, Inc.$31,110Research paymentCash or cash equivalent2023
2023-08-04Apellis Pharmaceuticals, Inc.$6,000Research paymentCash or cash equivalentPhase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex 2023
2023-08-04Apellis Pharmaceuticals, Inc.$1,350Research paymentCash or cash equivalentA Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)2023
2023-08-03Janssen Research & Development, LLC$39,766Research paymentCash or cash equivalentA Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co2023
2023-08-01SANOFI US SERVICES INC.$61,947Research paymentCash or cash equivalentREGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis2023
2023-08-01Genentech, Inc.$2,500Research paymentCash or cash equivalentPh IIb of Astegolimab in COPD2023
2023-08-01Genentech, Inc.$500Research paymentCash or cash equivalentPh IIb of Astegolimab in COPD2023
2023-07-31Janssen Research & Development, LLC$5,658Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2023
2023-07-27Alexion Pharmaceuticals, Inc.$28,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-07-27Genentech, Inc.$2,975Research paymentCash or cash equivalentPh IIb of Astegolimab in COPD2023
2023-07-27Alexion Pharmaceuticals, Inc.$672Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-07-26United Therapeutics Corporation$41,174Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA2023
2023-07-26Merck Sharp & Dohme LLC$5,056Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot2023
2023-07-25Paratek Pharmaceuticals, Inc.$19,461Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTICA Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe2023
2023-07-25United Therapeutics Corporation$2,052Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-07-19Genentech, Inc.$7,000Research paymentCash or cash equivalentTecentriq Biological, BioOncology1LM SCLC Tecentriq Lurbinectedin2023
2023-07-19Luminex Corporation$44HonorariaIn-kind items and servicesARIES Device, Device2023
2023-07-14Boehringer Ingelheim Pharmaceuticals, Inc.$93,249Research paymentCash or cash equivalentPDE4 Phase III trial in IPF patients2023
2023-07-13SANOFI US SERVICES INC.$3,400Research paymentCash or cash equivalentRandomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Sm2023
2023-07-13SANOFI US SERVICES INC.$2,666Research paymentCash or cash equivalentRandomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Sm2023
2023-07-11United Therapeutics Corporation$6,282Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2023
2023-07-04Regeneron Pharmaceuticals, Inc.$336Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-07-01SANOFI US SERVICES INC.$61,947Research paymentCash or cash equivalentREGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis2023
2023-06-29Apellis Pharmaceuticals, Inc.$31,915Research paymentCash or cash equivalent2023
2023-06-29Alexion Pharmaceuticals, Inc.$5,700Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-06-29Apellis Pharmaceuticals, Inc.$500Research paymentCash or cash equivalent2023
2023-06-29Alexion Pharmaceuticals, Inc.$435Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-06-28Novartis Pharmaceuticals Corporation$273,830GrantIn-kind items and services2023
2023-06-28Regeneron Pharmaceuticals, Inc.$336Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-06-26Insmed, Inc.$2,432Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$1,691Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$1,662Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$1,633Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$1,574Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$1,415Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$1,000Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcom2023
2023-06-26Insmed, Inc.$1,000Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$1,000Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$1,000Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcom2023
2023-06-26Insmed, Inc.$1,000Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-06-26Insmed, Inc.$1,000Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-06-26Insmed, Inc.$629Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$629Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$629Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$500Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcom2023
2023-06-26Insmed, Inc.$500Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-06-26Insmed, Inc.$500Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$300Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso2023
2023-06-26Insmed, Inc.$287Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2023
2023-06-26Genentech, Inc.$223Research paymentCash or cash equivalentTecentriq Biological, BioOncologyNeoadjuvant NSCLC2023
2023-06-22Novartis Pharmaceuticals Corporation$172,650GrantIn-kind items and services2023
2023-06-20Regeneron Pharmaceuticals, Inc.$336Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-06-14GENZYME CORPORATION$376Research paymentCash or cash equivalentNEXVIAZYME Biological, Genetic DiseaseAn Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ2023
2023-06-13Regeneron Pharmaceuticals, Inc.$392Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023
2023-06-12PFIZER INC.$30,013Research paymentCash or cash equivalentXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANTWI206744 2015 ASPIRE US CHANGE IN SERUM AND SPUTUM BIOMARKERS OVER TIME IN THE DEVELOPMENT OF RHEUMATOID ARTHRITISASSOCI2023
2023-06-06Paratek Pharmaceuticals, Inc.$11,784Research paymentCash or cash equivalentNUZYRA Drug, ANTIBIOTICA Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe2023
2023-06-06Roche Products Limited$4,242Research paymentCash or cash equivalentEsbriet Biological, ImmunologyPh III OLE Trial to Evaluate Long term Safety and Efficacy of PRM 151 in Patients with IPF2023
2023-06-02Apellis Pharmaceuticals, Inc.$61,775Research paymentCash or cash equivalent2023
2023-06-02Apellis Pharmaceuticals, Inc.$500Research paymentCash or cash equivalent2023
2023-06-01SANOFI US SERVICES INC.$61,947Research paymentCash or cash equivalentREGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis2023
2023-05-25Alexion Pharmaceuticals, Inc.$28,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-05-25Alexion Pharmaceuticals, Inc.$15,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-05-24Regeneron Pharmaceuticals, Inc.$1,232Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2023

The latest 200 records of 321.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Denver CountyDenver city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Denver, CO, county Denver County, CO, state Colorado; placed by its city name.

MeasurePlace (city or town)
Denver, CO
County
Denver County, CO
State
Colorado
Population B01003718,877718,8775,862,189
Population, 2020 census P1715,522715,5225,773,714
Median age B0100235.335.337.7
Under 18 B0100118.0%18.0%21.0%
65 and over B0100112.5%12.5%15.6%
Households B11001335,428335,4282,374,218
Foreign born B0500214.5%14.5%9.8%
Median household income B19013$94,718$94,718$95,470
Median family income B19113$124,743$124,743$119,139
Per capita income B19301$64,163$64,163$52,636
Poverty rate B1700111.2%11.2%9.4%
Unemployment rate B230254.9%4.9%4.6%
Civilian labor force B23025447,681447,6813,235,476
Mean commute (minutes) B0801324.924.925.2
Bachelor's degree or higher B1500356.5%56.5%45.7%
Housing units B25001359,581359,5812,589,053
Owner-occupied B2500348.8%48.8%66.2%
Renters B2500351.2%51.2%33.8%
Median home value B25077$616,000$616,000$539,400
Median gross rent B25064$1,831$1,831$1,761
White, not Hispanic B0300254.0%54.0%64.8%
Black B030028.6%8.6%3.8%
Hispanic or Latino B0300228.0%28.0%22.5%
Asian B030023.6%3.6%3.2%
American Indian and Alaska Native B030020.3%0.3%0.4%

Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); Unemployment rate: 3.0% in Sep 2016 to 4.1% in Sep 2026; low 2.4%, high 11.7% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, CO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.